Zenith Capital (Zenith Capital) Price-to-Tangible-Book : (As of Jun. 18, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Price-to-Tangible-Book?

As of today (2024-06-18), Zenith Capital's share price is $0.15. Zenith Capital's Tangible Book per Share of . 20 for the quarter that ended in . 20 was $0.00. Hence, Zenith Capital's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Zenith Capital's Price-to-Tangible-Book or its related term are showing as below:

ZHCLF's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.71
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Zenith Capital's share price is $0.15. Zenith Capital's Book Value per Sharefor the quarter that ended in . 20 was $0.00. Hence, Zenith Capital's P/B Ratio of today is .

Zenith Capital Price-to-Tangible-Book Historical Data

The historical data trend for Zenith Capital's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Price-to-Tangible-Book Chart

Zenith Capital Annual Data

Trend

Price-to-Tangible-Book

Zenith Capital Quarterly Data

Price-to-Tangible-Book

Competitive Comparison of Zenith Capital's Price-to-Tangible-Book

For the Biotechnology subindustry, Zenith Capital's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Price-to-Tangible-Book falls into.

Zenith Capital Price-to-Tangible-Book Calculation

Zenith Capital's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: . 20 )
	=	0.15	/
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Zenith Capital Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines